Short Interest in Spero Therapeutics, Inc. (NASDAQ:SPRO) Declines By 24.0%

Spero Therapeutics, Inc. (NASDAQ:SPRO) saw a significant decrease in short interest in February. As of February 13th, there was short interest totaling 715,694 shares, a decrease of 24.0% from the January 29th total of 941,659 shares. Approximately 1.3% of the company’s stock are short sold. Based on an average daily volume of 426,955 shares, the short-interest ratio is currently 1.7 days. Based on an average daily volume of 426,955 shares, the short-interest ratio is currently 1.7 days. Approximately 1.3% of the company’s stock are short sold.

Wall Street Analyst Weigh In

Several research firms recently commented on SPRO. Wall Street Zen upgraded shares of Spero Therapeutics from a “hold” rating to a “buy” rating in a report on Sunday, January 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Spero Therapeutics in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Spero Therapeutics currently has a consensus rating of “Reduce”.

Spero Therapeutics Price Performance

Shares of SPRO stock traded up $0.02 on Monday, hitting $2.19. The company’s stock had a trading volume of 104,193 shares, compared to its average volume of 301,973. The stock has a market capitalization of $123.10 million, a price-to-earnings ratio of -2.77 and a beta of 1.45. Spero Therapeutics has a fifty-two week low of $0.51 and a fifty-two week high of $3.22. The firm’s fifty day moving average price is $2.36 and its 200-day moving average price is $2.25.

Insider Activity at Spero Therapeutics

In other news, insider Esther Rajavelu sold 87,917 shares of Spero Therapeutics stock in a transaction on Friday, February 6th. The stock was sold at an average price of $2.36, for a total transaction of $207,484.12. Following the transaction, the insider owned 1,012,091 shares in the company, valued at approximately $2,388,534.76. The trade was a 7.99% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 5.50% of the stock is currently owned by company insiders.

Institutional Trading of Spero Therapeutics

Large investors have recently modified their holdings of the company. Invesco Ltd. bought a new position in Spero Therapeutics in the 2nd quarter worth $43,000. State Street Corp grew its holdings in Spero Therapeutics by 10.1% in the 4th quarter. State Street Corp now owns 210,151 shares of the company’s stock valued at $490,000 after buying an additional 19,200 shares during the last quarter. Millennium Management LLC bought a new position in Spero Therapeutics in the 4th quarter worth approximately $56,000. Dimensional Fund Advisors LP bought a new position in Spero Therapeutics in the 3rd quarter worth approximately $55,000. Finally, Quadrature Capital Ltd acquired a new position in shares of Spero Therapeutics during the second quarter worth approximately $90,000. 25.60% of the stock is owned by institutional investors.

Spero Therapeutics Company Profile

Spero Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug‐resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.

The company’s lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections caused by resistant Gram‐negative pathogens.